GlassScriptPhysician profile
Todd A Dorfman
NPI 1619180403
$9,163.24
in general payments reported to CMS, 2019-2025
36 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $295 · 2021: $1,104 · 2022: $2,544 · 2023: $1,623 · 2024: $2,118 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,950.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,708.21 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $1,132.88 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $793.06 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $585.33 | 2019-2025 | |
| Boston Scientific Corporation | $569.16 | 2019-2025 | Watchman Flx, Watchman Access System, Avvigo Guidance System |
| Pfizer INC. | $533.85 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.79 | 2022-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $353.65 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $271.98 | 2019-2024 | Farxiga |
| Esperion Therapeutics, INC. | $249.71 | 2021-2023 | Nexletol |
| Cardiovascular Systems INC. | $215.04 | 2021-2023 | Diamondback Coronary |
| Angiodynamics, INC. | $211.34 | 2022-2025 | Alphavac |
| Astellas Pharma US INC | $211.01 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $166.86 | 2022-2023 | Arcalyst |
| Amarin Pharma, INC. | $157.66 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $154.96 | 2023-2024 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $145.63 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $142.65 | 2024-2025 | Onpattro |
| Shockwave Medical, INC | $123.91 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Sanofi-Aventis U.S. LLC | $113.22 | 2023-2024 | |
| Philips North America LLC | $105.99 | 2022-2024 | (Ck4) Mcot |
| Edwards Lifesciences Corporation | $102.26 | 2022-2023 | |
| Abbott Laboratories | $86.53 | 2021-2023 | Cardiomems |
| Novo Nordisk INC | $82.31 | 2022-2023 | Wegovy, Rybelsus, Ozempic |
| Lundbeck LLC | $81.63 | 2019-2020 | |
| Inari Medical, INC. | $69.17 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Cmp Pharma, INC. | $68.93 | 2022-2023 | Carospir, Norliqva, Tadliq |
| Cordis US Corp. | $46.74 | 2024 | Mynx Control, Infiniti |
| Actelion Pharmaceuticals US, INC. | $33.99 | 2021 | |
| Hologic Sales and Service, LLC | $25.10 | 2023 | Aptima |
| Abiomed | $24.76 | 2019 | |
| Medtronic, INC. | $24.17 | 2023 | Cobalt Dr Mri Surescan |
| Acist Medical Systems, INC. | $18.91 | 2022 | |
| Heartflow, INC. | $16.99 | 2022 | |
| Lilly USA, LLC | $16.97 | 2024 | Zepbound, Jardiance |
| Chiesi USA, INC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Dorfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.